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Abstract
Background: Neuroblastoma (NB) tumors are well known for their pronounced clinical and molecular
heterogeneity. The global gene expression and DNA copy number alterations have been shown to have profound
differences in tumors of low or high stage and those with or without MYCN amplification. RNA splicing is an
important regulatory mechanism of gene expression, and differential RNA splicing may be associated with the
clinical behavior of a tumor.
Methods: In this study, we used exon array profiling to investigate global alternative splicing pattern of 47
neuroblastoma samples in stage 1 and stage 4 with normal or amplified MYCN copy number (stage 1-, 4- and 4+).
The ratio of exon-level expression to gene-level expression was used to detect alternative splicing events, while the
gene-level expression was applied to characterize whole gene expression change.
Results: Principal component analysis (PCA) demonstrated distinct splicing pattern in three groups of samples.
Pairwise comparison identified genes with splicing changes and/or whole gene expression changes in high stage
tumors. In stage 4- compared with stage 1- tumors, alternatively spliced candidate genes had little overlap with
genes showing whole gene expression changes, and most of them were involved in different biological processes.
In contrast, a larger number of genes exhibited either exon-level splicing, gene-level expression or both changes in
stage 4+ versus stage 1- tumors. Those biological processes involved in stage 4- tumors were disrupted to a
greater extent by both splicing and transcription regulations in stage 4+ tumors.
Conclusions: Our results demonstrated a significant role of alternative splicing in high stage neuroblastoma, and
suggested a MYCN-associated splicing regulation pathway in stage 4+ tumors. The identification of differentially
spliced genes and pathways in neuroblastoma tumors of different stages and molecular subtypes may be
important to the understanding of cancer biology and the discovery of diagnostic markers or therapeutic targets in
neuroblastoma.
Background
Alternative splicing of pre-messenger RNA is nearly uni-
versal, involving more than 90% of human genes [1]. It
is an important regulatory mechanism of gene expres-
sion for tissue-specific functions. Each gene maintains a
delicate balance of its alternative transcripts in normal
cells, disruption of which affects normal cellular pro-
cesses and may cause various diseases, including cancer
[2]. Although there have been numerous studies to iden-
tify tumor-specific splicing va r i a n t sa sd i a g n o s t i cm a r -
kers or therapeutic targets, only recently has alternative
splicing in cancer been studied using genome-wide pro-
filing methods [3-7]. Most of these studies focus on the
identification of splicing variants in tumor, while little
has been explored on the role of alternative splicing in
tumors of different stages and molecular subtypes.
Neuroblastoma is the most common solid extracranial
tumor in children. The incidence rate is 10.2 cases per
million children under 15 years of age, and the median
age at diagnosis is 17 months [8]. Stage, age, and other
biological features in tumour cells are important
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management. The “International Neuroblastoma Staging
System” (INSS) classifies the tumor into six stages (1,
2A, 2B, 3, 4, 4S) according to its anatomical presence at
diagnosis [9]. Localized disease has favorable outcome
with an overall survival rate for stage 1 disease of 75-
90%. Patients over 18 months with stage 4 disease has a
2-year disease-free survival rate of only 30-40% [10].
MYCN is the most important biologic marker for neuro-
blastoma. It is amplified in approximately 25% of de
novo neuroblastoma cases and is more common in
patients with advanced-stage disease. MYCN-amplified
tumor is highly aggressive with poor outcome [11].
Alternative splicing has been shown to be involved in
neuroblastoma development [12]. For example, kinesin
family member 1B isoform beta (KIF1Bbeta) but not
alpha is down-regulated in advanced stages of neuro-
blastoma. KIF1Bbeta induces apoptotic cell death, sug-
gesting its role as a haploinsufficient tumor suppressor
[13,14]. In this study, we used Affymetrix Human Exon
1.0 ST Array (HuEx) to measure exon expression levels
in 47 neuroblastoma samples of different clinical stages
and molecular subtypes including stage 1 with normal
MYCN copy number (1-), stage 4 with MYCN amplifica-
tion (4+) or normal MYCN copy number (4-). The goal
was to identify stage- and MYCN amplification-specific
splicing patterns in comparison to whole gene expres-
sion changes for the understanding of cancer biology
and discovery of biomarkers or therapeutic targets in
neuroblastoma.
Results
Identification of alternatively spliced candidate genes
To study the role of splicing regulation in high stage
and MYCN amplified neuroblastoma, we used HuEx
array to measure exon expression levels in 47 neuro-
blastoma samples from 10 stage 1-, 28 stage 4-, and 9
s t a g e4 +t u m o r s( T a b l e1 ) .H u E xa r r a ya l l o w st h e
detection of differential inclusion or skipping of exons
by measuring expression levels of individual exons in
different groups of samples. Alternative splicing events
may be detected by normalized intensity (NI), which is
defined as the ratio of exon-level probeset expression
to gene-level transcript cluster expression [15]. To
examine the global splicing pattern in neuroblastoma,
we performed principal component analysis (PCA)
using NI values of all core probesets (n = 221,809)
across all samples after quality filtering. Figure 1 shows
that stage 1- and 4+ samples are clearly separated from
each other, while stage 4- samples are located between
the other two groups. The separation of three groups
of tumors by NI values suggests distinct alternative
splicing patterns associated with clinical stage and
MYCN status.
Probesets with significantly different NI values in
two groups of samples represent exons that may be
differentially spliced in two disease states. We used
Significant Analysis of Microarray (SAM) procedure
[16] with a stringent false discovery rate threshold (q
value < 0.05) to compare NI among three groups of
patients. There were 1501 differentially spliced candi-
date genes between 4- and 4+, while only 362 genes
were differentially spliced between 1- and 4-. Using
AltAnalyze, we checked prior evidence of alternative
splicing in Ensembl and/or UCSC genome browser
databases [17]. Of the candidate gene lists derived
from the comparison of 4-/4+ and 1-/4- tumors, 44.7%
(671) of the former list and 29.6% (107) of the latter
were supported by prior evidence of alternative spli-
cing. The largest difference was between 4+ and 1-
with 2775 differentially spliced candidate genes, of
which 46.9% (1302) had alternative exons with prior
evidence of alternative splicing (Additional file 1,
Figure 2A). Therefore, both stage and MYCN amplifi-
cation seem to affect the alternative splicing patterns
in neuroblastoma.
Potential impact of alternative splicing in neuroblastoma
To estimate the functional impact of alternative splicing,
we predicted changes in domain, motif, and miRNA
binding site composition of protein sequences for alter-
natively regulated exons in stage 1-, 4-, and 4+ tumors
[17]. The percentage of alternative exons that were asso-
ciated with predicted domain/motif change ranges from
74.1% to 76.2% for the pair-wise comparison of three
tumor groups. The number of genes including at least
one alternative domain/motif were 296 (81.8%) for stage
4- vs 1-, 1181 (78.7%) for stage 4+ vs 4-, and 2203
(79.4%) for stage 4+ vs 1- respectively. In addition to
the impact on protein domain/motif, alternative splicing
may result in gain or loss of miRNA binding sites. Our
analysis identified 19, 280, and 538 genes containing
alternative exons overlapping with predicted miRNA
binding sites for the comparison of 4-/1-, 4+/4-, and 4
+/1- tumors, respectively. These results suggested
diverse changes in protein function and expression regu-
lated by alternative splicing in high stage neuroblastoma.
Several known aberrant splicing events in neuroblas-
toma and/or other tumors are evident in our candidate
lists. For example, exon array data indicated decreased
expression of KIF1Bbeta but not KIF1Balpha in high
stage neuroblastoma, which is consistent with previous
report (Additional file 2) [18].
More interestingly, our results showed increased
expression of M2 isoform of PKM2 in high stage neuro-
blastoma while the M1 isoform exhibited decreased
expression (Figure 3). The splicing switch of pyruvate
kinase has been demonstrated in multiple tumor types
Guo et al. BMC Medical Genomics 2011, 4:35
http://www.biomedcentral.com/1755-8794/4/35
Page 2 of 11Table 1 Tumor samples used in the study
Year of Diagnosis Age at Diagnosis (years) INSS Stage MYCN Amplification Status Clinical Outcome Years of Survival
NB7 1998 1.3 1 NA A 5.2
NB8 1998 4.6 4 NA D 1.8
NB9 1996 1.1 1 NA A 7.1
NB17 2000 1.2 1 NA A 3.5
NB21 2000 5.2 4 AMP D 0.6
NB24 2000 0.6 4 NA A 3
NB27 2000 10.5 4 AMP D 1.4
NB29 1998 0.3 1 NA A 5.1
NB30 1997 0.9 4 NA A 5.9
NB31 1998 1.4 4 NA A 6.7
NB32 1998 1.2 4 NA A 5.7
NB33 1998 1.4 1 NA A 4.8
NB34 1997 1.2 1 NA A 5.2
NB205 1995 3.9 4 NA D 2.3
NB206 1995 2.7 4 NA D 5.8
NB207 1995 4.4 4 NA D 3.1
NB208 1995 0.8 1 NA A 4.8
NB210 1996 2.5 4 NA D 1.1
NB221 1997 0.4 1 NA A 5.7
NB237 1999 4.0 1 NA A 3.2
NB238 1999 1.1 1 NA A 3
NB265 1996 1.8 4 AMP D 2
NB266 1996 2.0 4 AMP D 0
NB269 1997 0.8 4 NA A 5.3
NB275 1995 1.6 4 NA D 1
NB278 1999 1.7 4 AMP D 0.8
NB282 1999 4.6 4 NA A 3.3
NB283 1999 5.5 4 NA D 4
NB500 1995 5.1 4 NA A 7.4
NB503 2000 3.9 4 NA A 3.3
NB504 2000 0.3 4 NA A 3.5
NB506 2000 0.3 4 NA A 3.9
NB508 2000 0.2 4 NA A 3.2
NB509 2000 3.0 4 NA D 4.1
NB510 2000 0.6 4 NA A 3.4
NB511 2001 0.1 4 NA A 3.0
NB514 2001 11.6 4 NA A 3.5
NB515 2001 3.9 4 NA A 3.2
NB521 1999 1.5 4 NA A 5.6
NB536 1998 3.1 4 NA D 1.2
NB540 1999 3.4 4 NA D 1.1
NB541 1999 9.6 4 AMP D 0.1
NB543 1999 11.4 4 NA D 1.4
NB545 1999 3.4 4 AMP D 2.2
NB547 2000 1.5 4 AMP D 3.8
NB548 2000 1.6 4 NA D 3.4
NB581 2002 1.6 4 AMP D 1.6
Abbreviations: INSS, International Neuroblastoma Staging System; AMP, amplification; NA, not amplified; A, alive without event; D, deceased due to
neuroblastoma disease.
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Page 3 of 11[19], but not previously reported in neuroblastoma. Two
isoforms are expressed through exchange of two cassette
exons, which are equally long and share 60% protein
sequence identity [20]. Functional annotation by AltA-
nalyze identified the gain of the allosteric activator fruc-
tose 1,6-bisphosphate (FBP) binding region and
intersubunit contact in high stage neuroblastoma, con-
sistent with the allosteric regulation of M2 isoform but
not M1 isoform by FBP [20]. The upregulation of M2
isoform in stage 4+ vs 1- tumors was also evident at the
proteome level demonstrated by a previous proteomics
study in our lab, which applied isotope-coded affinity
tags (ICAT) in combination with mass spectrometry to
quantify peptide expression levels in stage 1- and 4+
tumors [21]. The quantitative ICAT analysis identified
five peptides matched against PKM2 protein sequence,
among which KCCSGAIIVLTKS was from the exon spe-
cific to the M2 isoform and the other four were from
constitutive exons in PKM2. M2 isoform-specific pep-
tide demonstrated a mean log2-transformed expression
ratio of 2.73, and the other peptides had a mean ratio of
1.67 between 4+ and 1- tumors ([21]). Although no pep-
tide has been found for M1 isoform-specific exon, the
higher expression change of M2 isoform-specific exon
than constitutive exons suggested the upregulation of
M2 isoform but not the M1 isoform at the proteome
level.
Alternative splicing and whole gene expression changes
in neuroblastoma
To compare global splicing and transcription regulation
in high stage neuroblastoma, we derived whole gene
expression signatures by pairwise comparison of gene-
level transcript cluster signals. Therefore, splicing signa-
ture includes genes having differentially included/
excluded exons between two tumor groups, while whole
gene expression signature are genes with different gene-
level signals of two tumor groups. SAM analysis resulted
in 185, 2318, and 3298 genes showing whole gene
expression changes for stage 1- vs 4-, 4- vs 4+, and 1-
vs 4+, respectively (FDR ≤ 0.05 and Fold Change ≥ 1.5;
Figure 2B, Additional file 3).
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Figure 1 Principal component analysis (PCA) of 47
neuroblastoma samples by log2-transformed normalized
intensity of core probesets. PCA was performed using NI values of
core probesets (n = 221,809) across all samples after quality filtering.
Stage 1- and 4+ samples are clearly separated from each other,
while stage 4- samples are located between them. Blue, stage 1-;
green, stage 4-; red, stage 4+ tumors.
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Figure 2 Comparison of exon level splicing change and gene
level expression change. Pairwise comparison of stage 1-, 4-, and
4+ tumors was performed for both exon level splicing change and
gene level expression change; the genes with FDR < 0.05 were
identified. (A) Venn diagram of alternatively spliced candidate genes.
(B) Venn diagram of differentially expressed candidate genes. (C)
Comparison of exon level splicing change and gene level
expression change. Blue column shows number of genes with
whole gene expression change but not splicing change, while red
column shows number of genes with splicing change but not
whole gene expression change. Green column represents genes
with both whole gene expression and splicing changes.
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Page 4 of 11Comparing stage 4- with 1-, only 27 genes were
shared between splicing signature (n = 362) and whole
gene expression signature (n = 185) (Figure 2C). Using
the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [22], we found that genes
with known splice variants were significantly overrepre-
sented in splicing signature (n = 153) but not expression
signature based on UniProt annotation (FDR < 0.05),
which indicated the validity of our splicing analysis pro-
cess. The most enriched Gene Ontology terms in the
biological process category in the splicing signature
included nervous system development, cell adhesion,
synaptic transmission, and cytoskeleton organization
and biogenesis (Figure 4A, Additional file 4). In contrast,
the whole gene expression signature is enriched with
genes involved in cell cycle, cell division, and DNA
metabolic processes (Figure 4B, Additional file 4), which
is consistent with the results derived using traditional
gene expression microarray platforms [23]. Different sets
of genes with different biological functions were affected
by alternative splicing and transcription regulation, sug-
gesting independent roles of splicing and transcription
regulation in stage 4- neuroblastoma.
MYCN amplified neuroblastoma is the most aggres-
sive disease subtype. By comparing stage 1- and stage
4+ neuroblastomas, we identified 9044 probesets
within 2775 alternatively spliced candidate genes, along
with 3298 differentially expressed genes between two
tumor groups. Again, significant enrichment of genes
with known splice variants (n = 311) was found in
those showing only splicing changes (n = 852), but not
those having only whole gene expression changes (n =
1375) (FDR < 0.05). In contrast to stage 4- tumors, a
large number of genes (n = 1923) appeared to have
both changes in stage 4+ tumors (Figure 2C). Biologi-
cal processes enriched in alternatively spliced genes in
stage 4+ include those involved in stage-specific spli-
cing signature and whole gene expression signature
(Table 2). Similar GO terms were enriched in genes
showing whole gene expression changes in stage 4+
(Additional file 5). To derive MYCN amplification-spe-
cific signatures, we compared stage 4- and 4+ tumor,
and detected 4602 probesets within 1501 genes that
may undergo splicing disruption, and 2318 transcript
clusters with expression changes during MYCN status
change. The overlap between two signatures was also
large with 1127 genes in common (Figure 2C). GO
enrichment analysis results were similar to what was
found in the comparison between stage 4+ vs 1-
tumors (Additional file 6). These results suggested a
correlation between MYCN amplification and splicing
regulation. While splicing and transcription regulation
may affect different sets of genes involved in different
biological processes in stage 4- tumors, these biological
processes may be disrupted by both gene expression
regulatory processes to a greater extent in the more
severe stage 4+ neuroblastoma.
Validation of splice variants differentially expressed in
stage 1- and stage 4+ tumors
Three alternatively spliced genes have been selected
for quantitative RT-PCR validation including
PKM2 (NM_002654 vs. NM_182470 & NM_182471),
KIF1B (NM_015074 vs. NM_183416) and MAP2
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Figure 3 Alternative splicing of pyruvate kinase (PKM2)
detected by Affymetrix exon (HuEx) array. (A) Gene structure of
known isoforms is shown on the top panel with predicted
domains/motifs that differ in protein isoforms. Green oval shows
intersubunit contact (ISC) sequence, and red boxes point to fructose
1,6-bisphosphate (FBP) binding regions as defined by UniProt. The
HuEx expression is shown on the bottom panel. Each point
represents mean log2-expression of each group that was then
median-centered across three groups. Orange lines point to
probeset 3631984 that mapped to the unique exon in isoform M1
(NM_182470 and NM_182471), and probeset 3631977 that mapped
to the unique exon in isoform M2 (NM_002654). While isoform M2-
specific probeset showed increased expression in stage 4+
compared to stage 4-/1- tumors, isoform M1-specific probeset
indicated lower expression in stage 4+ tumor. (B) Normalized
intensity (NI) values for probeset 3631984 in Stage 1-, 4- and 4+
tumors. (C) Normalized intensity values for probeset 3631977 in
Stage 1-, 4- and 4+ tumors. The expression for probesets 3631984
and 3631977was significantly different between stage 1- and 4+,
suggesting the increased expression of isoform M2 and reduced
expression of isoform M1 in MYCN-amplified neuroblastoma.
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Page 5 of 11(NM_001039538 vs. NM_002374). Figure 5 shows gene
expression fold changes between splice variants in 5
stage 1- and 5 stage 4+ tumors. The HuEx results for all
three alternatively spliced genes were validated by qRT-
PCR result and the expression of splice variants is sig-
nificantly different between stage 1- and stage 4+
tumors with p-values (t-test) equal to 0.0038, 0.0014
and 0.0209 for genes PKM2, KIF1B and MAP2 respec-
tively. The expression of M2 isoform (NM_002654) of
PKM2 is increased in stage 4+ compared with M1 iso-
form; the expression of KIF1Bb (NM_015074) is
decreased in stage 4+ compared with KIF1Ba
(NM_002374); and the expression of isoform
NM_001039538 of MAP2 is higher in stage 4+ com-
pared with the isoform NM_002374.
Discussion
Alternative splicing of precursor mRNA is an essential
step in gene expression and responsible for much of the
proteome diversity in mammalian genomes. Although
splice variants have long been known to be associated
with many human diseases, very little is understood
about the global properties of alternative splicing in can-
cer development. Using Affymetrix Human 1.0 exon
array, we compared splicing interruption and whole
gene expression change in different stages of a pediatric
cancer - neuroblastoma. Our results suggested a signifi-
cant role of splicing regulation in high stage and MYCN
amplified neuroblastoma tumors.
In stage 4- neuroblastoma, transcription regulation
and alternative splicing may affect different sets of genes
(A)
(B) 5.0E-2 < 5.0E-7
Figure 4 Enriched Gene Ontology (GO) biological processes in alternatively spliced (A) or differentially expressed (B) genes in stage 4-
vs 1- neuroblastomas. GO enrichment analysis was done by DAVID [22], and overrepresented biological processes were shown as a GO graph
in which child terms are connected to their parent terms by directed lines. Color scale denotes Benjamini-corrected p-values generated by a
hypergeometric test, and node size is proportional to the number of genes annotated to corresponding GO terms.
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Page 6 of 11involved in different biological processes with more
genes showing splicing disruption than whole gene
expression change. Regulation of transcription and spli-
cing seem to be two independent processes that result
in distinct functional outcomes in stage 4- tumor, which
is consistent with the independent roles of these two
processes in determination of tissue specificity [24] and
regulation of immune response [25]. In contrast, a large
group of genes underwent both splicing and whole gene
expression changes in stage 4+ tumor. Similar biological
processes were enriched in splicing and whole gene
expression signatures in stage 4+ tumor, including those
that were affected separately by alternative splicing and
w h o l eg e n ee x p r e s s i o nc h a n g e si ns t a g e4 -t u m o r .I t
indicates that different biological processes may be
affected by splicing and transcription regulation in stage
4- tumors and these processes may need to be disrupted
by both gene regulatory processes in the more severe
stage 4+ tumors.
MYCN-amplified tumor is a highly aggressive subtype
with poor prognosis in 20% of neuroblastoma patients.
Several studies have shown the differential expression of
a large number of genes involved in cell cycle and differ-
entiation in these tumors [23,26]. Our current study
indicates, for the first time, that MYCN amplification is
not only related to large scale gene expression changes
but also profound splicing regulation in neuroblastoma.
MYCN is a global transcriptional regulator for both
Table 2 Top 40 overrepresented Gene Ontology
biological processes (FDR < 0.0001) in alternatively
spliced genes in stage 4+ vs. 1- tumors
GO Term # Gene PValue
cell cycle process ** 203 2.26E-15
mitotic cell cycle ** 107 8.64E-15
cellular component organization and biogenesis * 572 1.07E-14
cell cycle ** 230 1.33E-14
cell cycle phase ** 115 2.03E-14
mitosis ** 84 2.29E-14
cell division ** 88 3.86E-14
M phase of mitotic cell cycle ** 84 4.03E-14
M phase ** 97 1.28E-13
organelle organization and biogenesis * 285 1.67E-13
developmental process 651 4.37E-12
nervous system development * 192 1.66E-10
multicellular organismal development 479 4.24E-10
cellular process 2167 4.71E-10
chromosome segregation 32 7.47E-10
anatomical structure development 441 1.43E-9
localization 610 1.10E-8
regulation of cell cycle ** 135 1.11E-8
cell cycle checkpoint 30 1.15E-8
cytoskeleton organization and biogenesis * 134 1.41E-8
system development 364 1.93E-8
regulation of progression through cell cycle ** 133 2.61E-8
DNA replication ** 74 7.81E-8
synaptic transmission * 84 2.63E-7
transmission of nerve pulse 93 2.98E-7
establishment of localization 533 5.36E-7
intracellular signaling cascade 307 6.77E-7
cell proliferation 179 7.05E-7
transport 516 7.30E-7
mitotic sister chromatid segregation 18 7.33E-7
response to DNA damage stimulus ** 86 1.18E-6
sister chromatid segregation 18 1.33E-6
biological adhesion * 173 1.67E-6
cell adhesion * 173 1.67E-6
DNA metabolic process ** 188 2.59E-6
cell communication 747 7.35E-6
interphase 34 1.15E-5
DNA replication initiation 16 2.45E-5
DNA-dependent DNA replication ** 36 2.54E-5
cell differentiation 355 2.55E-5
* GO terms that are also enriched in alternatively spliced genes in stage 4- vs
1- tumors.
** GO terms that are also enriched in differentially expressed genes in stage
4- vs 1- tumors.
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Figure 5 qRT-PCR validation on splice variants differentialy
expressed in stage 1- and stage 4+ tumors. Quantitative RT-PCR
was performed for three spliced genes including PKM2 (NM_002654
vs. NM_182470 & NM_182471), KIF1B (NM_015074 vs. NM_183416)
and MAP2 (NM_001039538 vs. NM_002374) in 5 stage 1- and 5
stage 4+ tumors. Differential expression of splice variants was
evaluated by calculating expression fold changes between splice
variants of the spliced gene in each sample, which were further
centered by median of values obtained in stage 1- and stage 4+
tumors. The expression of splice variants is significantly different
between stage 1- and stage 4+ tumors for all three tested spliced
genes.
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RNA products [27,28]. Transcriptional targets for
MYCN include splicing factors [29] which may in turn
regulate alternative splicing of various target genes.
Recent study has shown that the splicing switch of pyru-
vate kinase in human gliomas may be controlled by c-
myc through splicing factors including polypyrimidine
tract binding protein (PTBP1) [30]. The PKM2 splicing
switch (Figure 3) and PTBP1 expression upregulation
we found in stage 4+ neuroblastoma (Additional file 3)
suggest a MYCN-controlled pathway for PKM2 splicing
in neuroblastoma. Other splicing targets of PTBP1 have
also been found in our splicing signatures of MYCN-
amplified tumors, including reticulon 4 (RTN4) [31] and
ROD1 regulator of differentiation 1 [32]. In addition,
multiple differentially expressed MYC/MYCN target
genes in stage 4+ tumor appear to be associated with
splicing processing complex, such as small nuclear ribo-
nucleoprotein polypeptides (SNRPA, SNRPB, SNRPD2),
dead-box polypeptides (DDX1, DDX18), RNA-binding
motif protein (RBM3), and cleavage and polyadenylation
specific factor (CPSF1) [29,33]. These splicing regulators
m a yb ei n v o l v e di nMYCN-associated splicing regula-
tion, through which MYCN may exert part of its pheno-
typic effects on neuroblastoma.
Alternative splicing plays important roles in various
diseases. It may be a direct cause of the disease, or a
modifier of disease susceptibility and severity [2]. In this
study, we identified candidate genes undergoing splicing
disruption in high stage and MYCN amplified neuro-
blastoma, which help the understanding of disease biol-
ogy. Neural development and cell adhesion genes
exhibit splicing changes in stage 4- disease, and they
undergo both splicing regulation and whole gene
expression level change in stage 4+ patients. Previous
proteomics study has demonstrated that proteins
involved in these processes are significantly suppressed
in stage 4+ neuroblastoma patients [21]. Our results
suggest that alternative splicing may be responsible, at
least partially, for the changes observed at the proteome
level. Defects in splicing machinery may cause alterna-
tive splicing and further whole gene expression changes
of neural development and adhesion genes, resulting in
the protein level changes observed in our previous
study.
Alternatively spliced candidate genes identified in this
study provides a useful resource for the discovery of
diagnostic biomarkers or therapeutic targets in neuro-
blastoma. One example is related to splicing switch of
PKM2 variants. Previous studies in multiple tumor types
have shown that M2 isoform is expressed while M1 iso-
form disappears during tumor development [34]. PKM2
plays important role in cancer metabolism, and it has
been proposed to be a potential metabolic target for the
treatment of cancer [19,35]. Our results demonstrated
the splicing switch of isoform M1 to isoform M2 in
high stage neuroblastoma (Figure 3), suggesting a similar
role of PKM2 in neuroblastoma development as in other
tumors [35]. Another interesting result is related to the
alternative splicing of microtubule associated genes. Our
data demonstrated that genes involved in microtubule-
associated process were significantly enriched in differ-
entially spliced candidate genes in stage 4+/4- vs stage
1- tumors. There were 57, 27, and 15 microtubule-asso-
ciated genes showing aberrant splicing pattern in stage 4
+ vs 1-, 4+ vs 4-, and 4- vs 1- respectively (Figure 4A;
Additional file 4, 5, 6). Among these genes, KIF1Bbeta
but not alpha has been shown to be a potential 1p36
tumor suppressor for neuroblastoma. Protein regulator
of cytokinesis 1 (PRC1) is essential for organization of
central spindle and midzone formation, whose interac-
tion with KIF2C has been shown to be involved in
breast cancer tumorigenesis [36]. Microtubule-associated
protein 2 (MAP2) has been shown to be a prognostic
marker for melanoma patients [37], and splice variants
of MAPT gene demonstrated opposite changes in nor-
mal versus prostate tumor [38]. Recent studies have sug-
gested a significant role of deregulated microtubule
dynamics in enhanced genomic instabilities and tumor
development [39]. Our results suggest that alteration of
microtubule dynamics by alternative splicing may be an
important pathogenetic mechanism in high stage neuro-
blastoma. Further functional study of these microtubule-
associated genes may reveal novel tumor suppressors or
oncogenes for neuroblastoma.
Conclusions
In summary, our study demonstrated the important
roles of splicing regulation in high-stage and MYCN
amplified neuroblastoma. There may be a generalized
shift in global splicing patterns synchronizing with the
development of malignant phenotypes of tumor cells.
Deciphering the “splicing code” is essential for our
understanding of cancer etiology and progression
pathway.
Methods
Tumor samples
We used 47 pretreatment primary neuroblastoma tumor
samples in our study. All patients were blinded and
anonymized to us. Our protocol was exempt from the
NIH Multiple Project Assurance and our research activ-
ity involving human subjects was exempt from the office
of Human Subjects Research (OHSR). The median age
of forty-seven patients at diagnosis was 1.6 years (range
0.1 - 11.6 years). Ten patients had stage 1 disease while
the remaining thirty-seven patients had stage 4 disease
of which nine demonstrated MYCN gene amplification.
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We extracted total RNA from tumor samples [40],
which were then processed and labeled using Affymetrix
whole transcript one-cycle labeling kit. After hybridiza-
tion to Affymetrix Human Exon 1.0 arrays, chips were
stained and scanned as per manufacturer’si n s t r u c t i o n s .
For data analysis, we used Affymetrix Power Tool (APT)
to get signal intensities for probesets and transcript clus-
ters. Probeset signals were estimated by PLIER and a
detection p-value was assigned to each probeset by
DABG algorithm. Gene-level signals were derived for
17800 transcript clusters comprised of core probesets
that are supported by RefSeq transcripts and full-length
mRNAs using IterPLIER algorithm. IterPLIER identifies
highly correlated probesets of each transcript cluster to
derive transcript cluster signal, thus gene-level expres-
sion estimate mostly includes the expression level of
constitutive exons, which reflects gene expression regu-
lation at the level of transcription and/or RNA stability
but not splicing. A probeset is considered to be
expressed in a sample if its detection p-value is less
than 0.05, and a transcript cluster is expressed if more
than half of its consisting probesets have p values less
than 0.05.
For each core probeset (~284,000), we calculated
normalized intensity (NI) which is probeset (exon-
level) intensity divided by transcript cluster (gene-
level) intensity in each sample. The comparison of NI
between two sample groups may reveal exons that are
differentially spliced in two groups. To reduce the false
positive rate in the splicing variant identification, sev-
eral filtering steps were applied to the signals of both
probesets and transcript clusters. First, the detection
p-value was used to remove probesets and transcript
clusters with undetectable signals. Probesets are
required to be expressed in >50% samples of at least
one group, while transcript clusters have to be
expressed in >50% samples of both sample groups.
Next, we removed probesets with very low variances
based on the interquantile range of probeset intensities
across all samples. The least variable 20% probesets
were discarded to reduce the number of cross-hybri-
dizing or non-responsive probesets. Thirdly, we set
expression values of less than 30 to 30 to reduce noise
[7]. Lastly, we reduced the effect of inaccurate annota-
tions by removing transcript clusters with more than
one annotated Entrez Gene identifiers as well as multi-
ple transcript clusters annotated by the same Entrez
Gene identifier.
After the filtering steps, we used the Significance Ana-
lysis of Microarray (SAM) [16] two class unpaired
method to identify probesets that have statistically sig-
nificant changes in NI values between two groups of
patients. Briefly, a score di is calculated for each
probeset to measure the relative difference in splicing
index between two groups of samples,
di =
NIi2 − NIi1
si + s0
where si is a pooled standard deviation over the two
groups of samples, and so is a small positive constant
that adjusts for the small variability in the data. These di
values are used to rank probesets on ascending order
and derive observed order statistics d(i). Then, a permu-
tation procedure (n = 100) is applied to get a set of per-
muted relative difference values and corresponding
order statistics for each probeset. The average of per-
muted order statistics is defined as the expected statistic
dE(i), which is plotted versus the observed statistic d(i)
in a scatter plot. The set of probesets that are away
from the d(i) = dE(i) l i n eb yad i s t a n c eg r e a t e rt h a na n
adjustable threshold Δ are called significant, and the
percentage of such probesets identified by chance (false
discovery rate) is estimated by the permuted dataset. In
our study, the threshold Δ was chose to achieve a false
discovery rate of 0.05, and the fold change of NI was
required to be more than 1.5. The analysis of SAM was
done by the R package samr. Similarly, differentially
expressed genes were identified by applying SAM on the
signal estimate of transcript clusters. Non-specific filter-
ing was applied to remove transcript clusters that are
only expressed in less than 20% of all samples. The false
discovery rate is also required to be less than 0.05, and
the signal fold change is more than 1.5.
For each probeset with significantly different NI
between two tumor groups, we used AltAnalyze to iden-
tify competitive transcript isoforms that contain or do
not contain the exon overlapping with that probeset.
Possible splicing events caused by the alternative exon
were classified into seven types (alternative N/C-termi-
nus, alternative cassette exon, alternative 5’/3’ splice site,
retained intron, bleeding exon) based on the comparison
of exon structures of competitive isoforms. Furthermore,
we predicted changes in protein domains/motifs and
miRNA binding sites associated with the probeset using
both competitive isoform analysis and direct alignment
method in AltAnalyze [17,41].
Gene-level signal was estimated by the IterPlier algo-
rithm, and it mostly includes the expression level of
constitutive exons, which reflects gene expression regu-
lation at the level of transcription and/or RNA stability
but not splicing.
Array data access and visualization
To facilitate exon array data access and visualization, we
have developed a novel database and visualization sys-
tem displaying both gene-level and exon-level
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(http://pob.abcc.ncifcrf.gov/cgi-bin/JK). Coupled with
exon array annotation tools, such as ArrayCheck [42],
this system allows easy query and visual inspection of
alternatively spliced exons. Clinical outcome was also
integrated with gene expression data such that Kaplan-
Maier plot may be dynamically generated for each pro-
beset and transcript cluster. The raw data and the pro-
cessed data are also available at http://www.ncbi.nlm.
nih.gov/geo/ (GEO accession: GSE27608).
Quantitative RT-PCR validation
One microgram of total RNA was reversely transcribed to
cDNA using Superscript II reverse transcriptase (Invitro-
gen) and random hexamer primer (Invitrogen) at 42°C for
1 hour. PCR reactions were performed with 40 cycles at
95°C for 30 sec, 60°C for 30 sec, and 72°C for 45 sec using
SYBR Green PCR Master Mix (Applied Biosystems) and
spicing variant-specific primers on ABI 7000 Sequence
Detection System (Applied Biosystems). Splice variant-spe-
cific primers were designed using Primer 3 program
(http://frodo.wi.mit.edu/primer3) and synthesized by Inte-
grated DNA Technologies. Primer sequences are as fol-
lows: PKM2 (NM_182470&NM_182471) forward 5’-CTA
TCC TCT GGA GGC TGT GC-3’, reverse 5’-GAG GCT
CGC ACA AGT TCT TC-3’; PKM2 (NM_002654) forward
5’-ATC GTC CTC ACC AAG TCT GG-3’, reverse 5’-GAA
GAT GCC ACG GTA CAG GT-3’;K I F 1 B a (NM_183416)
forward 5’- GAA GAT CGA AGA CGT CAT GGC C-3’,
reverse 5’-ACA CCA GCA CCA ACA GGC TCC-3’;
KIF1Bb (NM_015074) forward 5’-ACT TCT AGC TGG
CAC AAT ACG-3’,r e v e r s e5 ’-GTC ACC GTC AAG AAT
CAC AAA G-3’; MAP2 (NM_002374) forward 5’-TGG
GTG GAC ACT CAA GAT GA-3’, reverse 5’-TGA TCT
CCG AGC TTC CTT TT-3’; MAP2 (NM_001039538) for-
ward 5’-GCT CTG GCT CCC AGT GTA TT-3’, reverse
5’-CTG CTG AGG TGG GCT GTA TT-3’.
To evaluate differential expression of splice variants in
stage 1- and stage 4+ tumors, we calculated expression
fold changes between different splice variants of the
spliced gene in each sample, which were further cen-
tered by median of values obtained in stage 1- and stage
4+ tumors.
Additional material
Additional file 1: Alternatively spliced candidate genes among
stage 1-, 4-, and 4+ tumors detected by HuEx exon array study
(FDR < 0.05).
Additional file 2: Alternative splicing of kinesin family member 1B
(KIF1B) detected by Affymetrix exon array. While KIF1Balpha-specific
probesets (6 probesets labeled by orange line) had no significant
expression change, KIF1Bbeta-specific probesets (31 probesets to the
right of the orange line) had significantly lower expression in high stage
tumors.
Additional file 3: Candidate genes with whole gene expression
changes among stage 1-, 4-, and 4+ tumors detected by HuEx exon
array study (FDR < 0.05).
Additional file 4: Gene Ontology enrichment of alternative spliced
and/or differentially expressed candidate genes in stage 4- vs 1-
tumors.
Additional file 5: Gene Ontology enrichment of alternative spliced
and/or differentially expressed candidate genes in stage 4+ vs 1-
tumors.
Additional file 6: Gene Ontology enrichment of alternative spliced
and/or differentially expressed candidate genes in stage 4+ vs 4-
tumors.
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